Respiratory News: Breaking Respiratory News, Comments and Articles. - Page: 2

21:37 EST 23rd November 2014 | BioPortfolio

Respiratory News - Page: 2Twitter RSS

Read the latest Respiratory News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Respiratory.

Search or Follow Our Respiratory - Page: 2 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Respiratory - Page: 2 News.
You can also follow our Respiratory - Page: 2 news stories on Twitter: @Respiratory_Bio

Showing "respiratory airways lungs breath" News Articles 26 to 50 of 2,900+

Wednesday 19th November 2014

Lee's gains China rights to Ikaria's INOmax

Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) received rights from Ikaria Inc. (Hampton, N.J.) to INOmax in China, Hong Kong, Macau and Taiwan. The inhaled nitric oxide to treat hypoxic respiratory failure associated with pulmonary hypertension in t...

We owe it to our patients to put on our game faces

When you walk into the emergency room to see a trauma patient, do you remind yourself as you enter the doors, “Keep your game face on?” When you finish a difficult surgery and make your way to the waiting area to review the prognosis with the family, do you tell yourself, “Take a deep breath. […]

New Data From Evolve Clinical Program Demonstrate SYNERGY™ Bioabsorbable Polymer Stent Meets Key Performance Endpoints

MARLBOROUGH, Mass., Nov. 19, 2014 /PRNewswire/ -- In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific (NYSE: BSX) SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure (TLF). Additionally, favorab...

Transgenomic Collaborates with Researchers to Advance Understanding of Genetic Disease Tuberous Sclerosis

Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that it is collaborating with the Tuberous Sclerosis Alliance (TS Alliance) by sharing its data on genetic variants in an inte...

New Data From Evolve Clinical Program Demonstrate SYNERGY™ Bioabsobable Polymer Stent Meets Key Performance Endpoints

MARLBOROUGH, Mass., Nov. 19, 2014 /PRNewswire/ -- In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific (NYSE: BSX) SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure (TLF). Additionally, favora...

BRIEF-Vectura gets marketing nod for Airflusal Forspiro in Ireland and Czech Republic

* Approval in Ireland and Czech Republic for innovative respiratory inhaler airflusal forspiro

Hill-Rom to Participate in the 26th Annual Piper Jaffray Healthcare Conference

CHICAGO, Nov. 19, 2014 /PRNewswire/ -- Hill-Rom Holdings, Inc. (NYSE: HRC) invites you to listen to a management presentation at the 26th Annual Piper Jaffray Healthcare Conference on December 2, 2014, at 9:00 a.m. EST. You are invited to listen to the live discussion via the internet link at http://ir.hill-rom.com/events.cfm or access it directly at http://www.media-server.com/m/p/6o93suny...

Inova Labs Introduces a New Lightweight 4L Portable Oxygen Concentrator with Best in Class Internal Battery Life

AUSTIN, Texas, Nov. 19, 2014 /PRNewswire/ -- Inova Labs Inc. ("Inova Labs"), a leading manufacturer of innovative oxygen therapy solutions is pleased to announce an addition to the Inova Labs family of portable oxygen concentrators with LifeChoice Activox™ 4L  ("Activox 4L"). The Activox 4L weighs only 4.8 pounds, and sets a new industry standard with its combination of size, p...

N30 Pharmaceuticals Secures $30 Million in Oversubscribed Crossover Financing

BOULDER, Colo., Nov. 19, 2014 /PRNewswire/ -- N30 Pharmaceuticals, Inc. ("N30 Pharma"), a clinical-stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis (CF), has raised $30 million in a mezzanine round of financing.  New investors include Wellington Management, RA Capital Management, LLC, Jennison Associates LLC (on behalf of certain clients), Rock Spri...

Parent Project Muscular Dystrophy Names Baltimore's Kennedy Krieger Institute a Certified Duchenne Care Center

HACKENSACK, N.J., Nov. 19, 2014 /PRNewswire-USNewswire/ -- Kennedy Krieger Institute in Baltimore, Maryland was named a Certified Duchenne Care Center by Parent Project Muscular Dystrophy (PPMD), the leading advocacy organization working to end Duchenne muscular dystrophy (Duchenne). Kennedy Krieger Institute is the fifth center to be certified by PPMD, recognizing the Institute's dedication ...

Discovery Labs Partners with March of Dimes on 2015 Prematurity Awareness Campaign

WARRINGTON, Pa., Nov. 19, 2014 /PRNewswire/ -- In recognition of Prematurity Awareness Month, Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care with an initial focus on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants, today announced that they are...

Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

PARIS AND TARRYTOWN, N.Y., Nov. 19, 2014 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCS...

Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

TARRYTOWN, N.Y. and PARIS, Nov. 19, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol).  Alirocumab is an investigational fully human monoclonal antibody targeting the ...

YogaVibes Launches a Huge Selection of Yoga Classes Online with Yoga Vida

YogaVibes introduces new online yoga videos with New York City’s popular yoga studio, Yoga Vida. Charlotte, NC (PRWEB) November 19, 2014 YogaVibes, a premium source of online yoga, is excited to introduce a new collection of online yoga videos with Yoga Vida. Co-founded in 2009 by Princeton University economics graduate, college ice hockey player, and Wall-Street-broker-turned-yogi Mike Patton...

Ikaria and Lee's Pharmaceutical Announce Strategic Partnership for the Registration and Commercialization of Ikaria's INOMAX® Total Care Package in the People's Republic of China, Hong Kong, Macau and Taiwan

HAMPTON, N.J. and HONG KONG, Nov. 19, 2014 /PRNewswire/ -- Ikaria, Inc. (through its INO Therapeutics subsidiary) and Lee's Pharmaceutical (HK) Limited today announced the signing of a strategic partnership for the registration and commercialization of Ikaria's INOMAX® Total Care package throughout the People's Republic of China, Hong Kong, Macau and Taiwan. Financial terms of the p...

Royalty Pharma Announces $3.3 Billion Royalty Transaction with Cystic Fibrosis Foundation Therapeutics

NEW YORK, Nov. 19, 2014 /PRNewswire/ -- Royalty Pharma announced today its acquisition of royalties on Vertex Pharmaceuticals' cystic fibrosis treatments owned by Cystic Fibrosis Foundation Therapeutics' ("CFFT"), an affiliate of the Cystic Fibrosis Foundation, for a cash payment of $3.3 billion. "We are honored to work with the Cystic Fibrosis Foundation on this extraordinary royalty transaction...

Treatment strategy may reduce infants' wheezing caused by virus

(Medical Xpress)—The antibiotic azithromycin may reduce the risk of recurrent wheezing in infants hospitalized with a common respiratory infection, according to a small pilot study at Washington University School of Medicine in St. Louis. Evidence ...

Tuesday 18th November 2014

Quit Smoking via Acupuncture with Flashpoint Acupuncture, Quakertown, PA

Quakertown, PA, November 19, 2014 --(PR.com)-- Flashpoint Acupuncture will be celebrating the Great American Smoke out, 2014 on Thursday, November 20, 2014. On this day, we will be offering $35 auricular acupuncture treatments from 4:00pm to 6:00pm. Treatments are in a group setting and will last between 20-30 minutes, the cost is $35 per person and a reservation is required. The sessions are gea...

Fort Worth Dental Expands Practice, Offers Laser Gum Disease Treatment to Weatherford Residents

Gum disease treatment using an innovative laser is now available for Weatherford, TX residents who are looking to treat their gum disease, at Fort Worth Dental. The LANAP® protocol offers patients suffering with gum disease symptoms, like bleeding gums, a minimally invasive and highly effective option for improving not only their oral health, but whole body health as well. Weatherford, TX (PR...

Pulmonary Hypertension Association Launches First Annual CTEPH Awareness Day

The Pulmonary Hypertension Association (PHA) has launched the first-ever CTEPH Awareness Day to raise awareness about Chronic Thromboembolic Pulmonary Hypertension (CTEPH) – a form of pulmonary hypertension that is caused by old, organized blood clots in the lungs.The organization is looking to BUST CTEPH by promoting Better Understanding, Screening and Treatment. Silver Spring, Md. (PRWEB) Nove...

Online Marketing Will Be a Boon for the Global Pulmonary Drug Delivery Systems Market from 2015 to 2019: TechNavio

TechNavio has announced the publication of its market research report on the Global Pulmonary Drug Delivery Systems Market, which is expected to grow at a CAGR of 8.90 percent from 2015-2019. An increase in the prevalence of respiratory diseases like asthma and

Sutter Care at Home Agencies Among Nation's 'Elite'

SACRAMENTO, Calif., Nov. 18, 2014 /PRNewswire/ -- Eight Sutter Care at Home locations in Northern California received a Top Agency award by the 2014 HomeCare Elite™ – the only performance recognition of its kind in the home health industry. Now in its ninth year, the HomeCare Elite identifies the top 25 percent of Medicare-certified home health agencies in the country. The eight Sutte...

Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis

ACR 20 response rates sustained with continued OTEZLA treatment through 104 weeks - 65.3 percent and 61.4 percent in PALACE 1 and 4, respectively Eighty four percent of patients who completed one year of treatment with OTEZLA continued on OTEZLA through week 104 in both trials The rates of most commonly reported adverse events of diarrhea...

Arrowhead Files for Regulatory Permission to Begin Phase 1 Trial of RNAi Therapeutic ARC-AAT

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a Phase 1 clinical trial of its RNAi-based therapeutic candidate, ARC-AAT, for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. ...

Generex Announces Collaboration on Medicinal Cannabis

WORCESTER, Mass. and TORONTO, Nov. 18, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that it has entered into a non-binding Letter of Intent (LOI) to license the Company's proprietary RapidMist™ drug delivery technologies to CannScience Innovations Inc. (CannScience) for the delivery of medicinal cannabis derived products into the...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks